Compare OSBC & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OSBC | MGTX |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2014 | 2018 |
| Metric | OSBC | MGTX |
|---|---|---|
| Price | $24.97 | $13.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $23.50 | ★ $24.57 |
| AVG Volume (30 Days) | 377.8K | ★ 677.5K |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | 1.02 | ★ 1.30 |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | $25.20 | $141.38 |
| Revenue Next Year | $3.66 | N/A |
| P/E Ratio | $24.45 | ★ $10.17 |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $16.65 | $6.62 |
| 52 Week High | $26.06 | $15.35 |
| Indicator | OSBC | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.33 | 44.70 |
| Support Level | $24.93 | $12.39 |
| Resistance Level | $25.95 | $15.33 |
| Average True Range (ATR) | 0.48 | 0.53 |
| MACD | -0.10 | -0.12 |
| Stochastic Oscillator | 33.96 | 20.40 |
Old Second Bancorp Inc is a bank holding company. It provides consumer and commercial banking products such as demand, money market, savings, time deposit, and individual retirement as well as commercial, industrial, consumer, and real estate lending, including installment loans, student loans, agricultural loans, lines of credit and overdraft checking, safe deposit operations, trust services, wealth management services, and additional services tailored to the needs of individual customers, corporates, small-medium enterprises. The company has one operating segment, which is community banking. The company's revenue consists of interest, commission, payments, and other income.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.